- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03291171
Identifying the Effect and Working Mechanisms of MyPlan 2.0 in Adults With Type 2 Diabetes
December 3, 2021 updated by: University Ghent
A Randomized Controlled Trial to Identify the Effect and the Working Mechanisms of MyPlan 2.0, a Self-regulation-based e- and mHealth Intervention Targeting Physical Activity and Sedentary Behaviour, in Adults With Type 2 Diabetes.
The aim of this study is to investigate whether and how 'MyPlan 2.0' helps adults with type 2 diabetes to be more physically active or less sedentary.
Two groups will be created, an intervention group and a waiting-list control group.
Study Overview
Detailed Description
The aim of this study is to investigate whether and how 'MyPlan 2.0' helps adults with type 2 diabetes to be more physically active or less sedentary.
Two groups will be created, an intervention group and a waiting-list control group.
Both groups will be tested during three testing waves: pretest, posttest and follow-up test.
Only the intervention group will be given acces to 'MyPlan 2.0'.
'MyPlan 2.0' consists of a website and mobile application targeting physical activity and sedentary behaviour.
The intervention has a duration of five weeks.
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ghent, Belgium, 9000
- Department of Movement and Sports Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years or older
- Type 2 diabetes
- Have access to internet
- Being computer literate
Exclusion Criteria:
- not Dutch Speaking
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group
Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
|
MyPlan 2.0 consists of five sessions.
During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
|
|
No Intervention: Waiting-list control group
Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in objective total, light and moderate-to-vigorous physical activity (PA)
Time Frame: Pretest, posttest (6 weeks) and follow-up (6 months)
|
Change in amount of total, light and moderate-to-vigorous physical activity, measured via accelerometers
|
Pretest, posttest (6 weeks) and follow-up (6 months)
|
|
Change in objective sedentary behaviour
Time Frame: Pretest, posttest (6 weeks) and follow-up (6 months)
|
Change in amount of total sitting time, measured via accelerometers
|
Pretest, posttest (6 weeks) and follow-up (6 months)
|
|
Change in self-reported total, light and moderate-to-vigorous physical activity (PA)
Time Frame: Pretest, posttest (6 weeks) and follow-up (6 months)
|
Change in amount of total, light and moderate-to-vigorous physical activity, measured via the International Physical Activity Questionnaire (IPAQ)
|
Pretest, posttest (6 weeks) and follow-up (6 months)
|
|
Change in self-reported sedentary behaviour
Time Frame: Pretest, posttest (6 weeks) and follow-up (6 months)
|
Change in amount of total sitting time, measured via the LASA sedentary behaviour self-report questionnaire
|
Pretest, posttest (6 weeks) and follow-up (6 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in self-efficacy
Time Frame: Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
Change in amount of self-efficacy to change behaviour, measured via 3 validated items (questionnaire)
|
Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
|
Change in outcome expectancies
Time Frame: Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
Outcome expectancies regarding the behaviour change, measured via 3 validated items (questionnaire)
|
Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
|
Change in risk perception
Time Frame: Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
Risk perception about the behaviour, measured via 3 validated items (questionnaire)
|
Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
|
Change in intention
Time Frame: Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
Amount of intention to change the behaviour, measured via 3 validated items (questionnaire)
|
Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
|
change in action planning
Time Frame: Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
Amount of action planning for behaviour change, measured via 3 validated items (questionnaire)
|
Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
|
change in coping planning
Time Frame: Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
Amount of coping planning for behaviour change, measured via 3 validated items (questionnaire)
|
Pretest, after week 1, after week 2, after week 3, after week 4, posttest (6 weeks), and follow-up (6 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ilse De Bourdeaudhuij, Professor, University Ghent
- Principal Investigator: Geert Crombez, Professor, University Ghent
- Principal Investigator: Maïté Verloigne, PostDoc, University Ghent
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 15, 2017
Primary Completion (Actual)
March 1, 2019
Study Completion (Actual)
March 1, 2019
Study Registration Dates
First Submitted
September 11, 2017
First Submitted That Met QC Criteria
September 19, 2017
First Posted (Actual)
September 25, 2017
Study Record Updates
Last Update Posted (Actual)
December 6, 2021
Last Update Submitted That Met QC Criteria
December 3, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MyPlan2.0_diabetes
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.